Asieris and ReviR Enter into Research Collaboration Agreement to Discover Oncology Therapeutics Based on ReviR’s Comprehensive Approach to RNA-targeting Technologies February 7, 2023
Asieris Enrolled First Patient for its Phase II Clinical Study of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer December 12, 2022
Asieris’ Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study December 12, 2022
Asieris named “2022 TOP 20 Most Influential Innovative Enterprises in Small Molecule Drugs” November 14, 2022
The Oral APL-1202 in Combination with PD-1 inhibitor Tislelizumab as Neoadjuvant Therapy has Entered Phase II Clinical Study November 11, 2022
Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis November 10, 2022
Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial November 4, 2022
Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance September 15, 2022
Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy August 25, 2022
Asieris on Science and Technology Innovation Board “2022 Most Innovative Companies” List August 22, 2022
Asieris’ Multinational Phase III Clinical Trial for the Non-Surgical Treatment of HSIL Has Completed Enrollment August 9, 2022
The First Domestic Case in Boao, Ushering in a New Option for Diagnosing Bladder Cancer August 8, 2022
Asieris to publish the study protocol of Cevira® as a novel treatment in patients with high grade squamous intraepithelial lesion (HSIL) on BMJ Open June 9, 2022
Asieris to present a study protocol of APL-1202 in combination with BeiGene’s tislelizumab as neoadjuvant therapy (NAC) for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting May 27, 2022
Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy April 15, 2022
World’s First Patient Dose Administered in Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients January 4, 2022
Bladder cancer diagnosis drug Hexvix® completed first patient procedure in Bo’ao Lecheng December 27, 2021
The CDE Approved IND Application to Investigate Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients October 13, 2021
Asieris Named One of Top 30 Chinese Innovative Enterprises in Small Molecule Drugs September 26, 2021
Asieris Appoints Dr. Alice Chen as Vice President, Discovery Biology and Head of Translational Research September 22, 2021
Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira® June 22, 2021
The U.S. FDA Approved IND Application to Investigate Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients June 14, 2021
Asieris and Sinopharm Enter into Strategic Partnership to Accelerate Commercialization of Asieris Products May 20, 2021
Asieris and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of APL-1202 and Tislelizumab May 6, 2021
Asieris Appoints Dr. Tie-Lin Wang as Senior Vice President, Head of Discovery Chemistry and Pre-Clinical Development April 8, 2021
Asieris and Photocure Expand Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan January 26, 2021
Asieris Appointed Dr. Yong Xue as Chief Medical Officer and Mr. Xinming Jiang as VP of Sales and Marketing January 25, 2021
Asieris Announces First Patient Enrollment in the Global Phase III Clinical Trial for APL-1702 November 12, 2020
Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent as First-line Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC) October 30, 2020
Asieris Received China NMPA’s Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL) July 8, 2020
Asieris Appointed Dr. Susan Wang as Senior Vice President of Global Business Development July 1, 2020
Asieris Announced the Completion of Series C+ Round Financing – to Accelerate the Commercialization June 28, 2020
Asieris Announced the Completion of Series C Round Financing- to Accelerate the Global Development of Its Innovative Drugs March 24, 2020
Asieris and Photocure Enter into a License Agreement for World-Wide Development and Commercialization of Cevira® July 2, 2019
Asieris’s Executives to Participate in the Upcoming Asia Pharma R&D Leaders Summit 2019 March 21, 2019
